Education
About Us
Working with TipRanks
Follow Us
Roche Holding Ltd (CH:RO)
:RO
RO Stock Chart & Stats
CHF335.20
-CHF4.40(-1.37%)
At close: 4:00 PM EST
CHF335.20
-CHF4.40(-1.37%)
Day’s Range― - ―
52-Week RangeCHF244.00 - CHF383.00
Previous CloseN/A
Volume5.14K
Average Volume (3M)28.08K
Market Cap
CHF293.78B
Enterprise ValueCHF318.19B
Total Cash (Recent Filing)CHF15.48B
Total Debt (Recent Filing)CHF31.64B
Price to Earnings (P/E)23.6
Beta1.33
Next Earnings
Jul 23, 2026EPS Estimate
10.76Next Dividend Ex-DateN/A
Dividend Yield2.88%
Share Statistics
EPS (TTM)8.38
Shares Outstanding106,691,000
10 Day Avg. Volume29,793
30 Day Avg. Volume28,076
Financial Highlights & Ratios
PEG Ratio0.36
Price to Book (P/B)7.73
Price to Sales (P/S)4.25
P/FCF Ratio18.55
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)20.29
Revenue Forecast (FY)CHF62.99B
Bulls Say, Bears Say
Bulls Say
Cash Generation & ProfitabilityConsistently strong operating and free cash flow provide durable funding for R&D, capital spending and dividends. Robust cash generation supports sustained pipeline investment, large manufacturing projects and shareholder returns even through revenue cyclicality.
Diversified Pharma + Diagnostics ModelDual‑division exposure combines high‑value, patent‑protected specialty medicines with recurring consumables and service revenue from diagnostics. This mix creates revenue stability and cross‑selling opportunities, cushioning pharma cyclicality and supporting long‑term margins.
Deep, Advancing PipelineA large cohort of NMEs advancing into Phase III materially increases Roche’s medium‑term product runway and risk‑adjusted growth prospects. More late‑stage assets raise the probability of future commercial launches and revenue diversification beyond current blockbusters.
Bears Say
China Diagnostics Pricing ReformsSustained pricing reforms in China structurally compress diagnostics revenue and margins in a critical market. Given China’s scale, prolonged weaker reimbursement materially reduces recurring consumables income and pressures segment profitability over the next several quarters.
Loss Of Exclusivity & BiosimilarsMaterial LOE hits and impending biosimilar entries erode protected revenue streams and pricing power for legacy biologics. These structural revenue losses require successful new launches or steady pipeline conversions to sustain long‑term top‑line and operating leverage.
Regulatory/Safety Uncertainty (BTK Class)Safety signals and heightened class scrutiny can delay approvals, restrict labels or trigger additional studies. For key late‑stage assets, such regulatory uncertainty raises development timelines and commercialization risk, potentially diminishing long‑term expected value from these programs.
Roche Holding Ltd News
RO FAQ
What was Roche Holding Ltd’s price range in the past 12 months?
Roche Holding Ltd lowest stock price was CHF244.00 and its highest was CHF383.00 in the past 12 months.
What is Roche Holding Ltd’s market cap?
Roche Holding Ltd’s market cap is CHF293.78B.
When is Roche Holding Ltd’s upcoming earnings report date?
Roche Holding Ltd’s upcoming earnings report date is Jul 23, 2026 which is in 142 days.
How were Roche Holding Ltd’s earnings last quarter?
Roche Holding Ltd released its earnings results on Jan 29, 2026. The company reported CHF8.375 earnings per share for the quarter, missing the consensus estimate of CHF8.515 by -CHF0.14.
Is Roche Holding Ltd overvalued?
According to Wall Street analysts Roche Holding Ltd’s price is currently Overvalued.
Does Roche Holding Ltd pay dividends?
Roche Holding Ltd pays a Annually dividend of CHF9.7 which represents an annual dividend yield of 2.88%. See more information on Roche Holding Ltd dividends here
What is Roche Holding Ltd’s EPS estimate?
Roche Holding Ltd’s EPS estimate is 10.76.
How many shares outstanding does Roche Holding Ltd have?
Roche Holding Ltd has 106,691,000 shares outstanding.
What happened to Roche Holding Ltd’s price movement after its last earnings report?
Roche Holding Ltd reported an EPS of CHF8.375 in its last earnings report, missing expectations of CHF8.515. Following the earnings report the stock price went up 1.79%.
Which hedge fund is a major shareholder of Roche Holding Ltd?
Currently, no hedge funds are holding shares in CH:RO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Roche Holding Ltd
Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Switzerland, Germany, the United States, Austria, Netherlands, the United Kingdom, France, Belgium, and internationally. The company offers pharmaceutical products for treating oncology, neuroscience, infectious, immunology, cardiovascular and metabolism, ophthalmology, and respiratory, as well as anemia, cancer, dermatology, hemophilia, inflammatory and autoimmune, neurological, and transplantation. It also offers in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and other diseases. In addition, the company supplies diagnostic instruments and reagents. The company was founded in 1896 and is headquartered in Basel, Switzerland.
Technical Analysis
Options Prices
Currently, No data available
---